Lethality of Alzheimer Disease and Its Impact on Nursing Home Placement
The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
This analysis evaluates the progression of Alzheimer disease (AD) severity and compares the life expectancy and nursing home placement rates for AD patients with the same measures in the general population. Data from the Consortium to Establish a Registry for Alzheimer Disease were analyzed to estimate expected survival, time spent in each Clinical Dementia Rating stage, and nursing home admission rate for a hypothetical cohort of patients aged 70 years with new-onset AD. Corresponding estimates for the US general population were calculated from the 2004 National Nursing Home Survey and the 2003 life table estimates from the US Census Bureau. Deaths from all causes by age 80 years are expected in 61% of AD patients and in 30% of the general population. From the age of 70 to 80 years, a typical AD patient spends 4 years at Clinical Dementia Rating stage 3 (severe), 3 years at stage 2 (moderate), and 3 years at stage 1 (mild). Nursing home admission by the age of 80 years is expected for approximately 75% of surviving AD patients, but for only 4% of the general population. Among persons aged > or =65 years, reported age-adjusted and sex-adjusted mortality rates for AD increased to 33% from 1999 to 2004.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“among people age 70, 61% of those with Alzheimer's dementia are expected to die before age 80 compared with 30% of people without Alzheimer's dementia.”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [384]
In the citing paper
“At age 80, approximately 75% of people with Alzheimer's dementia live in a nursing home compared with only 4% of the general population age 80. 384”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [384]
In the citing paper
“A person who lives from age 70 to age 80 with Alzheimer's dementia will spend an average of 40% of this time in the severe stage.384”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [384]
In the citing paper
“among people age 70, 61% of those with Alzheimer's dementia are expected to die before age 80 compared with 30% of people without Alzheimer's dementia.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [414]
In the citing paper
“A person who lives from age 70 to age 80 with Alzheimer's dementia will spend an average of 40% of this time in the severe stage.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [414]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370 · cited 11×
“A substantial impact on life expectancy is manifested early in the course of AD.”
BackgroundInfluentialSelf-citationThe incidence of dementia: A meta-analysis
Jorm, A. F., & Jolley, D. (1998) · Neurology · doi:10.1212/wnl.51.3.728 · Cited by 903
Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603
Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease
Mittelman, M. S., Haley, W. E., Clay, O. J., & Roth, D. L. (2006) · Neurology · doi:10.1212/01.wnl.0000242727.81172.91 · Cited by 602 · cited 1×
“Improving availability of and access to caregiver support and home care services may reduce the need for patient care in institutionalized settings.(41) FIGURE 1.”
BackgroundSurvival after Initial Diagnosis of Alzheimer Disease
Larson, E. B., Shadlen, M.-F., Wang, L., McCormick, W. C., Bowen, J. D., Teri, L., & Kukull, W. A. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00008 · Cited by 543
Seshadri, S., Wolf, P. A., Beiser, A., Au, R., McNulty, K., White, R., & D'Agostino, R. B. (1997) · Neurology · doi:10.1212/wnl.49.6.1498 · Cited by 489 · cited 2×
“In contrast, the corresponding risk for developing AD is nearly 12%.(43) Among men aged 70 years, the remaining lifetime risk for developing prostate cancer is 12%, with the corresponding AD risk being lower, at 6%.”
BackgroundMorris, J. C., McKeel, D. W., Storandt, M., Rubin, E. H., Price, J. L., Grant, E. A., Ball, M. J., & Berg, L. (1991) · Neurology · doi:10.1212/wnl.41.4.469 · Cited by 473
Survival Following a Diagnosis of Alzheimer Disease
Brookmeyer, R., Corrada, M. M., Curriero, F. C., & Kawas, C. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1764 · Cited by 407 · cited 12×
“A substantial impact on life expectancy is manifested early in the course of AD.”
BackgroundInfluentialUnited States life tables, 2003.
Arias, E. (2006) · PubMed · Cited by 375
Alzheimer Disease and Mortality: A 15-Year Epidemiological Study
Ganguli, M., Dodge, H. H., Shen, C., Pandav, R. S., & DeKosky, S. T. (2005) · Archives of Neurology · doi:10.1001/archneur.62.5.779 · Cited by 297
Weight loss in Alzheimer disease
Gillette-Guyonnet, S., Nourhashémi, F., Andrieu, S., de Glisezinski, I., Ousset, P. J., Rivière, D., Albarède, J.-L., & Vellas, B. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.637s · Cited by 280 · cited 1×
“Maintaining proper nutrition is a particular challenge for an AD patient, as weight loss often precedes diagnosis and contributes to the increased mortality risk.(40) Health care professionals will need to broach these uncomfortable topics or provide information on support groups and associations that offer assistance.”
BackgroundBerg, L., McKeel, D. W., Miller, J. P., Baty, J., & Morris, J. C. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540040011008 · Cited by 257
Stern, Y., Tang, M. X., Denaro, J., & Mayeux, R. (1995) · Annals of Neurology · doi:10.1002/ana.410370508 · Cited by 252
Stern, Y., Albert, M., Brandt, J., Jacobs, D. M., Tang, M.-X., Marder, K., Bell, K., Sano, M., Devanand, D. P., Bylsma, F., et al. (1994) · Neurology · doi:10.1212/wnl.44.12.2300 · Cited by 237
A Method for Estimating Progression Rates in Alzheimer Disease
Doody, R. S., Massman, P., & Dunn, J. K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.449 · Cited by 194
A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline
Suh, G., Ju, Y., Yeon, B. K., & Shah, A. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1168 · Cited by 177
Dementia: The leading predictor of death in a defined elderly population: The Cache County Study
Tschanz, J. T., Corcoran, C., Skoog, I., Khachaturian, A. S., Herrick, J., Hayden, K. M., Welsh-Bohmer, K. A., Calvert, T., Norton, M. C., Zandi, P., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000118210.12660.c2 · Cited by 155
Modelling Mini Mental State Examination changes in Alzheimer's disease
Mendiondo, M. S., Ashford, J. W., Kryscio, R. J., & Schmitt, F. A. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000615/30)19:11/12<1607::aid-sim449>3.0.co;2-o · Cited by 153
Adams and Victor’s Principles of Neurology, 9th ed
(2009) · Archives of Neurology · doi:10.1001/archneurol.2009.258 · Cited by 127
ALZHEIMER'S DISEASE AND OTHER DEMENTIAS
Orange, J. B., & Ryan, E. B. (2000) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(05)70015-x · Cited by 123
Risk of Death from Alzheimer's Disease in a Community Population of Older Persons
Evans, D. A., Smith, L. A., Scherr, P. A., Albert, M. S., Funkenstein, H. H., & Hebert, L. E. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116102 · Cited by 120
Measuring Alzheimer’s disease progression with transition probabilities: Estimates from CERAD
Neumann, P. J., Araki, S. S., Arcelus, A., Longo, A., Papadopoulos, G., Kosik, K. S., Kuntz, K. M., & Bhattacharjya, A. (2001) · Neurology · doi:10.1212/wnl.57.6.957 · Cited by 113 · cited 2×
“Life expectancy was calculated for patients with AD by using transition probabilities from the Consortium to Establish a Registry for Alzheimer Disease (CERAD).(31) The CERAD publication is unique in that it presents transition probabilities through the various CDR stages, in addition to the nursing home admission and…”
MethodSelf-citationTreatment for Breast Cancer in Patients with Alzheimer's Disease
Gorin, S. S., Heck, J. E., Albert, S., & Hershman, D. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.00467.x · Cited by 109 · cited 1×
“The observed lethality of AD may, in part, be due to therapeutic nihilism directed toward what might otherwise be potentially reversible concurrent medical conditions, as AD patients receive less treatment for breast cancer than the stage-matched and age-matched controls.(11) In addition, AD contributes to the risk of…”
BackgroundEaker, E. D., Vierkant, R. A., & Mickel, S. F. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00498-x · Cited by 105 · cited 11×
“A substantial impact on life expectancy is manifested early in the course of AD.”
BackgroundInfluentialAdjusted Mortality After Hip Fracture: From the Cardiovascular Health Study
Robbins, J. A., Biggs, M. L., & Cauley, J. A. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00985.x · Cited by 86 · cited 1×
“Patients with AD are at an increased risk for hip fractures,(13) which dramatically increases mortality.(14) Despite the impact of AD, evidence suggests that the lay public(15) and even clinicians are not well informed about its progression and lethality.”
BackgroundMurman, D. L., & Colenda, C. C. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523030-00004 · Cited by 76
Jones, R. W., McCrone, P., & Guilhaume, C. (2004) · Drugs & Aging · doi:10.2165/00002512-200421090-00005 · Cited by 63
Undiagnosed Diseases in Patients with Dementia – A Potential Target Group for Intervention
Löppönen, M. K., Isoaho, R. E., Räihä, I. J., Vahlberg, T. J., Loikas, S. M., Takala, T. I., Puolijoki, H., Irjala, K. M., & Kivelä, S.-L. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000080126 · Cited by 58
Textbook of Clinical Neurology, 2nd ed
Ziegler, D. K. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.804-a · Cited by 52
Cost Effectiveness of Memantine in???Moderately Severe to Severe Alzheimer???s Disease
Fran??ois, C., Sintonen, H., Sulkava, R. O., & Rive, B. (2004) · Clinical Drug Investigation · doi:10.2165/00044011-200424070-00001 · Cited by 49
Degenerative Dementias and Their Medical Care in the Movies
Segers, K. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31802f2460 · Cited by 39 · cited 1×
“Nearly three-quarters of Americans report knowing little or nothing at all about the cause or course of AD(15); they may assume that AD is a relatively benign disease, as it is often displayed in the lay media and commercial films.(19) This lack of knowledge occurs despite nearly universal awareness and despite one th…”
BackgroundCaselli, R. J., & Boeve, B. F. (2007) · Elsevier eBooks · doi:10.1016/b978-141603618-0.10033-5 · Cited by 16
Rate of Progression of Mental Decline in Alzheimer Disease: Summary of European Studies
Bracco, L., Piccini, C., & Amaducci, L. A. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199812000-00016 · Cited by 15
Dementia and Memory Disturbances
Marshall, F. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6109-0.00116-7 · Cited by 2
O1–02–02: Worldwide variation in the doubling time of Alzheimer's disease incidence rates
Ziegler‐Graham, K., Brookmeyer, R., Johnson, E., & Arrighi, H. M. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.04.088 · Cited by 1
Self-citation
Cited by
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
“Regardless of the cause of death, among people age 70, 61 percent of those with Alzheimer’s are expected to die before age 80 compared with 30 percent of people without Alzheimer’s [192].”
Influential2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
“On average, a person with AD will spend more years (40% of the total number of years with AD) in the most severe stage of the disease than in any other stage [119].”
Influential2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
“At age 80, approximately 75 percent of people living with Alzheimer’s dementia are expected to live in a nursing home compared with only 4 percent of the general population at age 80 [258].”
Influential
Metadata
- Authors
- Arrighi, H. M., Neumann, P. J., Lieberburg, I. M., & Townsend, R. J.
- Affiliations
- Elan Pharmaceuticals, Inc. (Ireland) (IE)
- Tufts Medical Center (US)
- University of California, San Francisco (US)
- Corresponding author
- Arrighi, Henry Michael
- Lieberburg, Ivan M.
- Townsend, Raymond J.
- ORCID
- Neumann, Peter J.
- Venue
- Alzheimer Disease & Associated Disorders
- Published
- 2010-01
- Volume
- 24
- Issue
- 1
- Pages
- 90-95
- ISSN
- 0893-0341 (ISSN-L)
- OpenAlex
- W2094938161
- Cited by
- 126
- References
- 36
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 9 · 2023: 10 · 2022: 14 · 2021: 11 · 2020: 6 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 14 · 2014: 11 · 2013: 6 · 2012: 4
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Alzheimer Disease & Associated Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Geriatrics and Gerontology › Geriatric Care and Nursing Homes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, mortality, nursing home admission, life expectancy, Clinical Dementia Rating, disease progression, survival estimates, mortality trends, older adults
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Homes for the Aged, Humans, Life Expectancy, Male, Nursing Homes, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.